Abstract
The Neuropathic Pain Special Interest Group of the International Association for the Study of Pain recently sponsored the development of evidence-based guidelines for the pharmacological treatment of neuropathic pain. Tricyclic antidepressants, dual reuptake inhibitors of serotonin and norepinephrine, calcium channel α2-δ ligands (ie, gabapentin and pregabalin), and topical lidocaine were recommended as first-line treatment options on the basis of the results of randomized clinical trials. Opioid analgesics and tramadol were recommended as second-line treatments that can be considered for first-line use in certain clinical circumstances. Results of several recent clinical trials have become available since the development of these guidelines. These studies have examined botulinum toxin, high-concentration capsaicin patch, lacosamide, selective serotonin reuptake inhibitors, and combination therapies in various neuropathic pain conditions. The increasing number of negative clinical trials of pharmacological treatments for neuropathic pain and ambiguities in the interpretation of these negative trials must also be considered in developing treatment guidelines. The objectives of the current article are to review the Neuropathic Pain Special Interest Group guidelines for the pharmacological management of neuropathic pain and to provide a brief overview of these recent studies.
| Original language | English (US) |
|---|---|
| Journal | Mayo Clinic Proceedings |
| Volume | 85 |
| Issue number | 3 SUPPL. |
| DOIs | |
| State | Published - 2010 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Recommendations for the pharmacological management of neuropathic pain : An overview and literature update. / Dworkin, Robert H.; O'Connor, Alec B.; Audette, Joseph; Baron, Ralf; Gourlay, Geoffrey K.; Haanpää, Maija L.; Kent, Joel L.; Krane, Elliot J.; LeBel, Alyssa A.; Levy, Robert M.; Mackey, Sean C.; Mayer, John; Miaskowski, Christine; Raja, Srinivasa N.; Rice, Andrew S C; Schmader, Kenneth E.; Stacey, Brett; Stanos, Steven; Treede, Rolf Detlef; Turk, Dennis C.; Walco, Gary A.; Wells, Christopher D.
In: Mayo Clinic Proceedings, Vol. 85, No. 3 SUPPL., 2010.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Recommendations for the pharmacological management of neuropathic pain
T2 - An overview and literature update
AU - Dworkin, Robert H.
AU - O'Connor, Alec B.
AU - Audette, Joseph
AU - Baron, Ralf
AU - Gourlay, Geoffrey K.
AU - Haanpää, Maija L.
AU - Kent, Joel L.
AU - Krane, Elliot J.
AU - LeBel, Alyssa A.
AU - Levy, Robert M.
AU - Mackey, Sean C.
AU - Mayer, John
AU - Miaskowski, Christine
AU - Raja, Srinivasa N.
AU - Rice, Andrew S C
AU - Schmader, Kenneth E.
AU - Stacey, Brett
AU - Stanos, Steven
AU - Treede, Rolf Detlef
AU - Turk, Dennis C.
AU - Walco, Gary A.
AU - Wells, Christopher D.
PY - 2010
Y1 - 2010
N2 - The Neuropathic Pain Special Interest Group of the International Association for the Study of Pain recently sponsored the development of evidence-based guidelines for the pharmacological treatment of neuropathic pain. Tricyclic antidepressants, dual reuptake inhibitors of serotonin and norepinephrine, calcium channel α2-δ ligands (ie, gabapentin and pregabalin), and topical lidocaine were recommended as first-line treatment options on the basis of the results of randomized clinical trials. Opioid analgesics and tramadol were recommended as second-line treatments that can be considered for first-line use in certain clinical circumstances. Results of several recent clinical trials have become available since the development of these guidelines. These studies have examined botulinum toxin, high-concentration capsaicin patch, lacosamide, selective serotonin reuptake inhibitors, and combination therapies in various neuropathic pain conditions. The increasing number of negative clinical trials of pharmacological treatments for neuropathic pain and ambiguities in the interpretation of these negative trials must also be considered in developing treatment guidelines. The objectives of the current article are to review the Neuropathic Pain Special Interest Group guidelines for the pharmacological management of neuropathic pain and to provide a brief overview of these recent studies.
AB - The Neuropathic Pain Special Interest Group of the International Association for the Study of Pain recently sponsored the development of evidence-based guidelines for the pharmacological treatment of neuropathic pain. Tricyclic antidepressants, dual reuptake inhibitors of serotonin and norepinephrine, calcium channel α2-δ ligands (ie, gabapentin and pregabalin), and topical lidocaine were recommended as first-line treatment options on the basis of the results of randomized clinical trials. Opioid analgesics and tramadol were recommended as second-line treatments that can be considered for first-line use in certain clinical circumstances. Results of several recent clinical trials have become available since the development of these guidelines. These studies have examined botulinum toxin, high-concentration capsaicin patch, lacosamide, selective serotonin reuptake inhibitors, and combination therapies in various neuropathic pain conditions. The increasing number of negative clinical trials of pharmacological treatments for neuropathic pain and ambiguities in the interpretation of these negative trials must also be considered in developing treatment guidelines. The objectives of the current article are to review the Neuropathic Pain Special Interest Group guidelines for the pharmacological management of neuropathic pain and to provide a brief overview of these recent studies.
UR - http://www.scopus.com/inward/record.url?scp=77950367410&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77950367410&partnerID=8YFLogxK
U2 - 10.4065/mcp.2009.0649
DO - 10.4065/mcp.2009.0649
M3 - Article
C2 - 20194146
AN - SCOPUS:77950367410
VL - 85
JO - Mayo Clinic Proceedings
JF - Mayo Clinic Proceedings
SN - 0025-6196
IS - 3 SUPPL.
ER -